BIOLASE, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2017-11-30: Form 8-K; Period of report 2017-11-30; Description 8.01 Other Events; Details 8.01.
- 2017-11-13: Form 8-K; Period of report 2017-11-08; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2017-11-09: Form 8-K; Period of report 2017-11-09; Description 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; Details 1.01.
- 2017-11-03: Form 8-K; Period of report 2017-11-03; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2017-11-30 | 8-K | 2017-11-30 | 8.01 Other Events | 8.01 On November 30, 2017, BIOLASE, Inc. (the “Company”) issued a press release announcing that the subscription period for its previously announced rights offering to holders of shares of its common stock expired at 5:00 p.m., Eastern Time, on November 29, 2017, and these rights are no longer exercisable. | d497333d8k.htm |
| 2017-11-13 | 8-K | 2017-11-08 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On November 8, 2017, the Board of Directors (the "Board") of Biolase, Inc. (the "Company") appointed Director Richard B. Lanman, M.D., to the Compensation Committee of the Board. | htm_55559.htm |
| 2017-11-09 | 8-K | 2017-11-09 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On November 9, 2017, the Company issued a press release announcing the commencement of the Company’s previously announced rights offering to holders of shares of its common stock. | d486923d8k.htm |
| 2017-11-03 | 8-K | 2017-11-03 | 8.01 Other Events | 8.01 On November 3, 2017, the Company issued a press release announcing the terms of the Company’s previously announced rights offering to holders of shares of its common stock. | biol-8k_20171103.htm |
| 2017-11-02 | 8-K | 2017-10-27 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 5.02 On October 27, 2017, Dr. Frederic H. Moll resigned from the Biolase, Inc. (the "Company") Board of Directors (the "Board"), effective November 11, 2017, due to other time commitments. | htm_55517.htm |
| 2017-11-01 | 8-K | 2017-11-01 | 2.02 Results of Operations and Financial Condition | 2.02 On November 1, 2017, BIOLASE, Inc. issued a press release announcing its financial results for the third quarter and nine months ended September 30, 2017. | biol-8k_20171101.htm |
| 2017-10-30 | 8-K | 2017-10-30 | 8.01 Other Events | 8.01 On October 30, 2017, Biolase, Inc. issued a press release announcing the record date of 5:00 p.m., Eastern Time on November 8, 2017, for its previously announced rights offering. | htm_55500.htm |
| 2017-10-03 | 8-K | 2017-09-30 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure; 8.01 Other Events | 5.02 On September 30, 2017, Biolase, Inc. (the "Company") entered into an employment agreement with John R. Beaver to serve as Senior Vice President and Chief Financial Officer of Biolase, effective October 1, 2017. | htm_55414.htm |
| 2017-09-29 | 8-K | 2017-09-26 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On September 29, 2017, the Company issued a press release to publicly announce its plans to complete a rights offering to existing holders of its common stock. | d457017d8k.htm |
| 2017-09-27 | 8-K | 2017-09-22 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On September 22, 2017, the Board of Directors (the "Board") of Biolase, Inc. (the "Company") appointed Director Jonathan T. Lord, M.D. to the Audit Committee of the Board and appointed Director James R. Talevich to the Compensation Committee of the Board. | htm_55398.htm |
| 2017-09-15 | 8-K | 2017-09-11 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On September 11, 2017, Harold C. Flynn, Jr., President and Chief Executive Officer of Biolase, Inc. (the "Company"), and Dmitri Boutoussov, Vice President of Research and Development of the Company, each agreed to receive restricted stock units in lieu of cash salary compensation for the period ending March 3, 2018. | htm_55355.htm |
| 2017-09-05 | 8-K | 2017-09-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On September 1, 2017, Mr. Paul N. Clark resigned from the Biolase, Inc. (the "Company") Board of Directors, effective September 11, 2017, and as Chairman of the Board, effective September 1, 2017, due to other time commitments. | htm_55310.htm |
| 2017-08-14 | 8-K | 2017-08-09 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On August 9, 2017, Biolase, Inc. (the "Company") received received a deficiency letter from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market ("Nasdaq") notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule"). | htm_55255.htm |
| 2017-08-07 | 8-K | 2017-08-07 | 2.02 Results of Operations and Financial Condition | 2.02 On August 7, 2017, BIOLASE, Inc. issued a press release announcing its financial results for the second quarter and six months ended June 30, 2017. | biol-8k_20170807.htm |
| 2017-07-10 | 8-K | 2017-06-30 | 3.02 Unregistered Sales of Equity Securities; 5.07 Submission of Matters to a Vote of Security Holders | 3.02 D Participating Convertible Preferred Stock, par value $0.001 per share, (the "Convertible Preferred Stock") and certain warrants (the "Warrants") to purchase up to an aggregate of 3,925,871 shares of the Company’s common stock, par value $0.001 per share (the "Common Stock"). 5.07 On June 30, 2017, a Special Meeting of Stockholders was held at the Company’s headquarters, 4 Cromwell, Irvine, California. | htm_55127.htm |
| 2017-05-16 | 8-K | 2017-05-10 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On May 10, 2017, the 2017 Annual Meeting of Stockholders of Biolase, Inc. (the "Company") was held at the Company's headquarters, 4 Cromwell, Irvine, California. | htm_54940.htm |
| 2017-05-03 | 8-K | 2017-05-03 | 2.02 Results of Operations and Financial Condition | 2.02 On May 3, 2017, BIOLASE, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2017. | biol-8k_20170503.htm |
| 2017-04-20 | 8-K | 2017-04-18 | 3.03 Material Modification to Rights of Security Holders; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 3.03 The disclosure set forth in Item 5.03 below is hereby incorporated into this Item 3.03 by reference. 5.03 On April 18, 2017, Biolase, Inc. (the "Company") filed a Certificate of Elimination of Biolase, Inc. (the "Certificate of Elimination") with the Secretary of State of the State of Delaware to eliminate from the Company’s certificate of incorporation all references to its Series C Participating Convertible Preferred Stock ("Series C Preferred Stock"). | htm_54834.htm |
| 2017-04-14 | 8-K | 2017-04-11 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 3.02 The disclosure set forth in Item 1.01 above under "Private Placement" is hereby incorporated into this Item 3.02 by reference. | htm_54809.htm |
| 2017-03-14 | 8-K | 2017-03-14 | 7.01 Regulation FD Disclosure | 7.01 On March 14, 2017, Harold C. Flynn, Jr., President and Chief Executive Officer of Biolase, Inc. (the “Company”), will deliver a presentation at the 29th Annual Roth Conference that will include a written communication comprised of slides. | d360906d8k.htm |
| 2017-03-08 | 8-K | 2017-03-08 | 2.02 Results of Operations and Financial Condition | 2.02 On March 8, 2017, BIOLASE, Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2016. | biol-8k_20170308.htm |
| 2017-03-01 | 8-K | 2017-02-23 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 1.01 Entry into a Material Definitive Agreement. 5.02 On February 23, 2017, the Board of Directors of Biolase, Inc. (the "Company") appointed Mark J. Nelson to serve as Chief Financial Officer and Senior Vice President of the Company, effective March 27, 2017. | htm_54644.htm |
| 2017-02-22 | 8-K | 2017-02-22 | 7.01 Regulation FD Disclosure | 7.01 On February 22, 2017, Harold C. Flynn, Jr., President and Chief Executive Officer of Biolase, Inc. (the “Company”), will participate in investor presentations during the 152nd Midwinter Meeting of the Chicago Dental Society in Chicago, Illinois that include a written communication comprised of slides. | d334522d8k.htm |
| 2017-01-13 | 8-K | 2017-01-13 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Effective as of January 13, 2017, David C. Dreyer resigned from his positions as Senior Vice President and Chief Financial Officer of Biolase, Inc. (the "Company"). | htm_54479.htm |
| 2017-01-09 | 8-K | 2017-01-09 | 7.01 Regulation FD Disclosure | 7.01 On January 9, 2017, Harold C. Flynn, Jr., President and Chief Executive Officer of Biolase, Inc. (the “Company”), will participate in investor presentations at the 35th Annual JP Morgan Healthcare Conference in San Francisco, California that include a written communication comprised of slides. | d321408d8k.htm |
| 2017-01-06 | 8-K | 2016-12-30 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 David C. Dreyer, the Company’s Senior Vice President and Chief Financial Officer, made a personal decision to leave the Company to pursue other opportunities. | htm_54458.htm |